EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Neuralgic Amyotrophy Following B‐Cell Maturation Antigen‐Directed CAR ‐T Therapy

Eduardo J Pérez-Torres iD, Daria V Madeeva, Adam D Cohen iD, Alfred L Garfall, Chafic Karam iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70358 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Eduardo J Pérez-Torres und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Brachial Plexus Neuritis, Receptors, Chimeric Antigen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Chimeric antigen receptor T‐cell (CAR‐T) therapy has transformed the management of refractory hematologic malignancies, but neurologic complications remain a major concern. While immune effector cell‐associated neurotoxicity syndrome is well recognized, peripheral neuropathies such as neuralgic amyotrophy have rarely been described.

Methods

We characterize the clinical, electrophysiologic, and imaging features of neuralgic amyotrophy after B‐cell maturation antigen (BCMA)‐directed CAR‐T therapy at a single tertiary care center.

Results

We identified four patients with neuralgic amyotrophy following BCMA‐directed CAR‐T therapy, corresponding to 1.5% of total patients treated in that time. Patients developed acute bilateral shoulder pain followed by weakness 8–12 days after CAR‐T infusion. Manifestations included scapular winging and arm weakness, with electromyography showing denervation most prominently in the muscles supplied by the long thoracic and suprascapular nerves. Corticosteroid use appeared to be associated with symptomatic improvement, although residual weakness persisted in most. Diagnosis was delayed in three patients due to misattribution of symptoms to other causes.

Discussion

Neuralgic amyotrophy may represent an underrecognized complication of BCMA‐directed CAR‐T therapy. The consistent timing of onset, bilateral involvement, and responsiveness to corticosteroids support an inflammatory mechanism. Clinicians should maintain vigilance for this complication, as prompt recognition and treatment may mitigate long‐term neurological morbidity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brachial Plexus NeuritisReceptors, Chimeric AntigenHumansFemaleMaleMiddle AgedElectromyographyAged

Stichwörter der Autor:innen

CAR‐Tbrachial plexopathycase serieschimeric antigen receptor T‐cell therapyneuralgic amyotrophy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Abramson Cancer Center, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Eduardo J Pérez-Torres, Adam D Cohen, Chafic Karam

Zitieren

APA

Pérez-Torres, E. J., Madeeva, D. V., Cohen, A. D., Garfall, A. L., & Karam, C. (2026). Neuralgic Amyotrophy Following B‐Cell Maturation Antigen‐Directed CAR ‐T Therapy. Muscle & Nerve. https://doi.org/10.1002/mus.70358

Vancouver

Pérez-Torres EJ, Madeeva DV, Cohen AD, Garfall AL, Karam C. Neuralgic Amyotrophy Following B‐Cell Maturation Antigen‐Directed CAR ‐T Therapy. Muscle & Nerve. 2026. doi:10.1002/mus.70358

BibTeX
@article{PrezTorres2026,
  author = {Pérez-Torres, Eduardo J and Madeeva, Daria V and Cohen, Adam D and Garfall, Alfred L and Karam, Chafic},
  title = {Neuralgic Amyotrophy Following B‐Cell Maturation Antigen‐Directed CAR ‐T Therapy},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70358}
}
Kostenlos starten →